Across TCGA pan-cancer cohorts, SLC44A3P1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of SLC44A3P1’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where SLC44A3P1 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC44A3P1 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.
BRCA are the cancer types where SLC44A3P1 tumor–normal differential expression is most reproducible.